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Abstract
Serous epithelial ovarian cancer (EOC) patients often succumb to aggressive metastatic disease, yet little is known about the
behavior and genetics of ovarian cancer metastasis. Here, we aim to understand how omental metastases differ from
primary tumors and how these differences may influence chemotherapy. We analyzed the miRNA expression profiles of
primary EOC tumors and their respective omental metastases from 9 patients using miRNA Taqman qPCR arrays. We find 17
miRNAs with differential expression in omental lesions compared to primary tumors. miR-21, miR-150, and miR-146a have
low expression in most primary tumors with significantly increased expression in omental lesions, with concomitant
decreased expression of predicted mRNA targets based on mRNA expression. We find that miR-150 and miR-146a mediate
spheroid size. Both miR-146a and miR-150 increase the number of residual surviving cells by 2–4 fold when challenged with
lethal cisplatin concentrations. These observations suggest that at least two of the miRNAs, miR-146a and miR-150, up-
regulated in omental lesions, stimulate survival and increase drug tolerance. Our observations suggest that cancer cells in
omental tumors express key miRNAs differently than primary tumors, and that at least some of these microRNAs may be
critical regulators of the emergence of drug resistant disease.
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Introduction
Serous Epithelial Ovarian Cancer (EOC) is an aggressive
disease for which there are few effective biomarkers and therapies.
EOC is often diagnosed after tumor cells have disseminated within
the peritoneal cavity [1]. Despite the fact that metastases account
for the majority of disease-related deaths, ovarian cancer
metastasis remains poorly understood [1].
The purpose of this study was to identify features that may be
important to establish metastases and to determine how these
factors may affect chemotherapy responses. Advanced metastatic
disease remains a daunting challenge to treat, most often leading
to recurrent, drug resistant tumors. Metastases can be enriched for
a distinct mutational spectrum compared to primary tumors
[2,3,4]. Comparing primary and metastatic tumors has generated
important insights into disease progression in both animal models
[5] and in patients [2]. To improve treatment of metastatic
disease, it is vital to understand the genes and pathways emerging
in metastases that may not be present in primary tumors. Although
metastatic potential can be predicted based on the primary tumor
[6,7], this observation is not mutually exclusive with the possibility
that key features emerge in metastases that are not observed in
primary tumors. For example, the new microenvironment can
induce significant phenotypic changes to cancer cells, including
changes to metabolic activity in the omentum [8], and increased
drug resistance [9].
Previous mRNA expression studies examining matched ovarian
primary and metastatic tumors from the same patient, support a
‘primary tumor predisposition’ model [6,10,11,12]. mRNA
expression data using early generation microarrays suggest there
are few significant expression differences between omental lesions
and primary tumors [13,14,15], however, numerous studies have
described differential expression of key regulatory factors between
primary tumors and metastases, including E-cadherin [16], MMPs
[17,18] and integrins [19]. To address this apparent discrepancy
and to gain new insights into the state of cancer cells in metastases,
we profiled miRNA expression in matched pairs of primary serous
epithelial ovarian (EOC) tumors and omental lesions. miRNA
expression profiling identifies miR-150 and miR-146a to be up-
regulated in omental metastases. We find that miR-150 and miR-
146a promote spheroid formation and increase the fraction of
residual surviving cells after cisplatin exposure. These observations
suggest that higher expression of miR-146a and miR-150 in
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e58226
omental lesions may lead to more aggressive, chemoresistant
disease.
Results
We identified 9 Stage IIIC serous epithelial ovarian cancer
patients with pairs of primary and omental metastatic tumor
specimens (Figure S1, Table S1). All patients were post-
menopausal (.55 years old at time of diagnosis) and had
metastatic disease in the omentum. We measured miRNA
expression using Taqman qPCR array cards in the 9 pairs of
tumors. Each tumor had .70% cancer cells, and good RNA
quality (Agilent Bioanalyzer RIN.5). Our focus is to understand
the changes manifesting during disease progression, and therefore
we have focused on comparing the metastases to the primary
tumors and did not consider normal ovarian epithelial cells.
Identification of miRNAs differentially expressed between
primary and metastatic tumors
We measured 377 miRNAs using ABI Taqman qPCR arrays,
specific for mature miRNAs [20], in 9 matched primary and
metastatic human tumors. 180 miRNAs are expressed, in at least
two tumors, with no global up- or down-regulation of these
miRNAs between the primary and metastatic tumors. Figure 1A
summarizes the miRNAs with large recurring expression differ-
ences as identified by a paired t-test (Figure S2). We tested the
expression of miR-146a and miR-150 in assays targeting just these
miRNAs in two pairs of patients to confirm that the Taqman
assays are specific for these miRNAs with no cross-talk from the
other 376 assays (Figure S3).
Hierarchical clustering of the fold change between primary and
metastatic tumors for the 17 miRNAs shows three distinct groups
(Figure 1B). Patients were clustered with similar fold changes in
miRNA expression (Figure 1B, left panel). Distinct miRNA groups
are more easily visualized when the miRNAs are clustered
independent of the patients (Figure 1B, right panel). Because
miR-146a, miR-21 and miR-150 are representative of the three
major up-regulated clusters, we decided to focus our efforts to
understand their possible functions in ovarian cancer. We found
that the expression of miR-21, miR-146a, miR-150 is negatively
correlated with their predicted mRNA targets (Figure S4),
suggesting that these miRNAs are actively suppressing mRNA
expression in metastases compared to primary tumors. We chose
to focus on miR-146a and miR-150 because these two miRNAs
have not previously been examined in ovarian cancer to our
knowledge.
To determine if the expression changes originate from cancer
cells or stroma, using an orthogonal assay, we performed in situ
hybridization (ISH). miR-21 is expressed in both cancer and
stroma cells, and up-regulated in omental lesions, consistent with
the Taqman qPCR screen (Figure 2A). By ISH, we observe that
the absolute expression levels are variable, but all 8 omental lesions
tested show increased miR-21 cancer cell expression compared to
the corresponding primary tumor (Figure 2 and Figure S5). In our
hands, ISH sensitivity is poor and depends on the quality of the
probe, and we were unable to obtain reliable signal for other
miRNAs, even after exhaustive examination of key variables
including hybridization temperature, proteinase K concentration,
and probe concentration. These observations suggest that miR-21
originates from both cancer and stroma cells, and that miR-21
expression increases in omental metastases in cancer cells.
In order to pursue a more global analysis, we enriched for
cancer cells by Laser Capture Microdissection (LCM) of H&E
stained cancer cells, and performed Taqman qPCR arrays from
two cases. 11 of the 17 miRNAs, identified in the bulk tumor
screen (Figure 1A), are expressed in LCM enriched cancer cells,
and the differential expression between primary tumors and
omental lesions is qualitatively the same (Figure 2B, Figure S6).
These observations suggest that the observed change in expression
likely originates in cancer cells for these 11 miRNAs (Figure 2B).
miRNAs not expressed in cancer cells, but with large expression
changes in the bulk tumor, such as miR-124 and miR-370, may
indicate the presence of specific types of stroma cells such as
fibroblasts or immune cells. We were initially intrigued by miR-
509-3-5p, miR-508-3p, and miR-508-5p as these were the only
miRNAs down-regulated in metastases in the bulk tumor
measurements. However, these three miRNAs are not expressed
in the LCM enriched cancer cell populations (Figure 2B), and are
not significantly expressed in the tested ovarian cancer cell lines
(Figure S7), and thus were not considered further.
Although LCM selected cancer cells are not 100% cancer cells,
these observations strongly suggest that miR-146a and miR-150
are likely expressed in cancer cells and that their expression is up-
regulated in omental metastases. Importantly, we find expression
of these miRNAs in H&E stained, LCM enriched cancer cells in
both primary and metastatic tumors, consistent with their likely
expression in cancer cells. TCGA has found that miR-150 and
miR-146a are expressed at low levels in most primary tumors [21],
consistent with our observations.
miR-150 and miR-146a promote spheroid formation
Taqman qPCR arrays revealed that 8 of the 17 metastatic
miRNAs (Figure 1A) are expressed in proliferating OVCAR-8 and
SKOV-3 cells (Figure S7) and in cancer cells in the human tumors
(Figure 2B). miR-146a is expressed at relatively low levels and
miR-150 is not significantly expressed as it was only detected
above the recommended Ct thresholds in the proliferating ovarian
cancer cell lines tested.
We hypothesized that miRNAs up-regulated in the omental
lesions would stimulate growth as part of their ability to promote
aggressive disease. We tested miRNAs expressed in cancer cells in
the tumors (Figure 2B) that are also modestly expressed in ovarian
cancer cell lines to avoid over-expressing miRNAs at supra-
physiological concentrations including miR-150, miR-146a, miR-
708, and miR-193a-5p. To model the higher miRNA expression
observed in omental lesions, we ectopically expressed synthetic
pre-miRs and performed gain of function screens in cell viability
and cisplatin sensitivity assays. Transfection of pre-miRs lead to
high overexpression of miR-146a (Figure S8, while miR-150 is
modestly expressed compared to U6 snRNA (DCt ,3). Ectopic
expression of miR-150 modestly increased the number of viable
cells in SKOV-3 and IGROV-1 over four days, but not in
OVCAR-8 cells (Figure 3). None of the other pre-miRs induced
significant, reproducible effects on growth in more than one cell
line.
Spheroids model multicellular aggregates in the ascites of
ovarian cancer patients that establish metastases [22]. Spheroids
are a more accurate representation of tumors and increasing
evidence suggests that drug responses are better modeled in
spheroids than in monolayer culture [23,24,25,26]. Spheroid
formation typically requires a minimum number of cells, followed
by spontaneous aggregation, survival under anchorage indepen-
dent conditions, and compaction to strengthen the survival of the
aggregate [27]. To evaluate miRNA function in spheroids, we
form uniform spheroids by seeding cells into agarose micromolds
[28]. Interestingly, all the expressed miRNAs are up-regulated in
3D spheroids compared to monolayer using a Taqman array card
(Figure S4). We tested miR-146a and miR-21 expression by
Ovarian Cancer Metastatic miRNAs
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Taqman qPCR, using primers targeting only these two miRNAs,
and reproducibly observe up-regulation of these two miRNAs in
spheroids (Figure 4A). To test if up-regulation of miR-146a is
important for spheroid formation, we inhibited miR-146a with a
Locked Nucleic Acid (LNA) inhibitor. miR-146a inhibition causes
amorphous, more loosely formed spheroids in both SKOV-3 and
OVCAR-8 cells after two days (Figure 4B), compared to the more
compact spheroids formed in the negative controls. The effect is
more dramatic in SKOV-3 than Ovcar-8. Because of the
amorphous nature of these early forming day 2 spheroids, we
could not reliably determine their sizes. This observation suggests
that early spheroid formation is impacted by a reduction of miR-
146a activity. After 4 days, when control spheroids have more fully
formed after undergoing compaction, inhibition of miR-146a with
a LNA inhibitor reduces spheroid size, compared to a negative
control LNA, in SKOV-3, but only modestly in OVCAR-8
(Figure 4C). 45 spheroids were measured in each replicate, and
three independent replicates were performed. The size of each
spheroid was determined by ImageJ and the size distribution of
spheroids is represented with box plots (Figure 4C and 4D).
Spheroid formation can be challenging due to slight differences in
the number of cells used to seed each spheroid. With agarose
molds, we evaluate a large number of spheroids to overcome
concerns with errors in cell number used to seed the spheroids in
each well allowing for distinct miRNA dependent differences to be
observed.
Consistent with increased expression of miRNAs in spheroids
being critical for spheroid formation, higher miR-150 and miR-
146a expression promote larger spheroids in SKOV-3 and
OVCAR-8 (Figure 4D). Introduction of miR-150 and miR-146a
show the most consistent and largest effects on spheroids
compared to the negative control and the other pre-miRs tested.
For miR-146a, we observe smaller spheroids when miR-146a is
inhibited (Figure 4C) and larger spheroids upon ectopic expression
Figure 1. miRNA expression profile of primary and metastatic ovarian tumors. A. miRNA expression profiling by Taqman qPCR arrays
identifies 17 miRNAs differentially expressed between 9 pairs of primary tumors and omental lesions. miRNAs with p,0.05 (paired t-test) were
selected. The expression level is presented as the mean +/2 standard error of the mean (s.e.m.) of the fold change using the DCt method relative to
U6 snRNA. Red, lower expression in metastases, blue, higher expression in metastases. B. Left, unsupervised hierarchical clustering of the fold
changes of the analyzed patients. Right, association plot analysis of miRNA expression identifies miRNA clusters indicated in red. Clustering was
performed in Gene-E ]50].
doi:10.1371/journal.pone.0058226.g001
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(Figure 4D) after 4 days of spheroid formation. Together, these
observations, support miR-146a promoting spheroid formation.
miR-150 and miR-146a increase cisplatin tolerance
Once metastases are established, ovarian cancer is very difficult
to treat as recurrent resistant tumors often re-emerge after initial
chemotherapy. Changes in miRNA expression may indicate a
different physiological state for the cancer cells in the metastases
affecting how these lesions would respond to chemotherapy. We
tested the effect of increased expression of four miRNAs, up-
regulated in omental lesions, on cisplatin sensitivity. Dose
dependent studies using Wst-1 assays reveal that higher expression
of miR-150 modestly increases the cisplatin IC50 in SKOV-3, but
not OVCAR-8 and IGROV-1 (Figure 5A). Other miRNAs, such
as miR-146a, affected either SKOV-3 or IGROV-1, but not both
in a statistically significant manner.
Careful examination of the cells in monolayer culture during
cisplatin treatment suggested that healthier cells survived with
higher expression miR-146a and miR-150 in high cisplatin
concentrations. The dynamic range of remaining cells is below
the detection limit of the Wst-1 assay. Recent studies have
identified reversible drug tolerant quiescent cells that survive lethal
concentrations of drugs [29]. Thus, examination of surviving cells
represents an alternative model to examine how cancer cells
survive chemotherapy. To test if the metastatic miRNAs promote
survival in lethal doses of cisplatin, we examined miRNA
expression in surviving residual cells in monolayer culture exposed
to lethal doses of cisplatin for 6–7 days. We find that miR-150 and
miR-146a are significantly up-regulated in the surviving cells
compared to the proliferating population (Figure 5C). miR-150 is
Figure 2. Validation of miRNA expression. A. In situ hybridization of miR-21. Cancer cells are stained red by Nuclear Red. Higher expression in
omental metastases is observed in each case even with both relatively high and low miR-21 expression in the primary tumor. The arrows indicate
regions of miR-21 expression co-localizing with Nuclear Red staining. B. Laser Capture Microdissection (LCM) of two cases reveals miRNAs likely
expressed in cancer cells. The heat map shows the fold change for the 17 miRNAs identified in the bulk tumor screen. Similar patterns of differential
expression are observed for the miRNAs expressed in cancer cells as observed in bulk tumor. Black indicates that the miRNA was not detectable in the
LCM isolated cancer cells.
doi:10.1371/journal.pone.0058226.g002
Figure 3. miR-150 promotes growth of ovarian cancer cells in monolayer. 24 hours after transfection with 50 nM pre-miRs, cells were plated
into 96 well plates and grown for 4 days. Viable cells were determined by Wst-1 normalized to cells transfected with negative control pre-miRs. Error
bars (s.e.m.) represent indendent biological triplicates. Each replicate consistes of consisting of three wells in a 96 well plate. **, p,0.01, *, p,0.05 by
Student’s t-test.
doi:10.1371/journal.pone.0058226.g003
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undetectable in OVCAR-8 cells and below the ABI recommended
threshold in SKOV-3 cells (Ct,36 cycles) in proliferating cells, but
becomes significantly expressed in residual surviving cells in both
cell lines, suggesting a possible role in surviving cisplatin. To test if
miR-146a affects the ability of ovarian cancer cells to survive long-
term cisplatin treatment, inhibition of miR-146a with LNAs
reduces the number of viable surviving residual cells modestly in
OVCAR-8, and more significantly in SKOV-3 cells (Figure 5D).
Consistent with their increased expression in the surviving cells, we
find that higher expression of miR-150 or miR-146a significantly
increases the number of surviving viable cells by trypan blue
exclusion assay, six (SKOV-3) or seven (OVCAR-8) days after
addition of lethal concentrations of cisplatin (Figure 5E). Trypan
blue is an indicator of the number of viable cells and reflects the
increased number of surviving cells we observed visually. Not all
the ectopically expressed miRNAs improve survival suggesting
that the effects of miR-150 and miR-146a are specific. These
observations suggest that increased expression of miR-150 and
miR-146a promote survival, or at least, delay cisplatin induced cell
death, in ovarian cancer cells.
Discussion
Our key findings demonstrate that metastatic tumors up-
regulate specific miRNAs compared to their primary tumors and
that, among these miRNAs, miR-146a and miR-150 promote 3D
spheroid formation and increase tolerance to cisplatin in ovarian
cancer cells, suggesting a role for these miRNAs for survival in
specific conditions. We observe significant common recurrence of
differential regulation of 17 miRNAs, suggesting that the
requirements to adapt to the omentum are very similar in the
majority of EOC patients. Together, these data support the idea
that omental lesions are enriched for features of aggressive disease,
which also mediate the patient’s response to chemotherapy. Some
Figure 4. miR-146a and miR-150 enhance spheroid formation. 24 hours after transfection with anti-miR LNA inhibitors or pre-miR mimics as
indicated, 700/ml SKOV-3 or 600/ml OVCAR-8 cells were seeded in 35 well agarose micromolds with one spheroid forming in each well. A. miR-21 and
miR-146a are up-regulated in 4 day SKOV-3 and OVCAR-8 spheroids detected using Taqman qPCR array cards in two replicates. Error bars are s.e.m. B.
Inhibition of miR-146a with 10 nM LNA delays spheroid formation and leads to more amorphous and looser formed spheroids in SKOV-3 and OVCAR-
8 after 2 days. Red bar is 400 mm. C. Box and whisker plot shows that inhibition of miR-146a with LNAs significantly reduces spheroid size after 4 days
in SKOV-3, and modestly in OVCAR-8. Representative expression shown from four replicates. D. Ectopic expression of miR-150 and miR-146a
significantly enhances spheroid formation after 4 days. SKOV-3 and OVCAR-8 cells were transfected with 50 nM of pre-miR miR-150 and miR-146a
pre-miRs before spheroid formation. SKOV-3 or OVCAR-8 cells were transfected as indicated. Representative spheroids are shown. Red bar is 400 mm.
Box and whisker plots of the size distribution of 45 spheroids from a representative experiment. Experiment was reproduced three times. P-values
determined by Student’s t-test.
doi:10.1371/journal.pone.0058226.g004
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of these features, such as miR-146a and miR-150 expression may
be unique to metastases, as they are very lowly expressed in most
primary tumors in our dataset and in TCGA [21]. Low expression
of these miRNAs in primary tumors is associated with poor overall
patient survival [21]. Because these miRNAs are often up-
regulated in omental lesions and highly correlated with expression
in primary tumors (Pearson = 0.7 for miR-150 and 0.78 for miR-
146a), we predict that higher expression in metastases will be
associated with shorter overall survival and disease progression.
One of the goals of this study was to understand how similar or
different primary ovarian tumors are from omental metastases.
Previous efforts comparing these tumors have applied microarray
technologies to examine mRNA expression levels. Using strict
thresholds, relatively small differences between primary and
metastatic tumors were reported [15]. However, a number of
studies report significant differences by other methods including
immunohistochemistry of E-cadherin [19], MMPs [17] and the
recent finding of adipocyte signaling affecting cancer cells in the
omentum [8]. miRNAs have emerged as key regulators of cell fate
and numerous miRNA profiling studies suggest that miRNAs may
have a larger dynamic range in their expression differences across
tissues allowing for the identification of distinct tissue and tumor
specific expression signatures.
Because the stroma cells differ between the two tumors, some of
the large miRNA expression differences could originate from these
cells. To identify which, if any, miRNA expression differences
originate from cancer cells, we performed two experiments. We
were able to detect miR-21 by ISH, which shows increased miR-
21 expression in H&E stained cancer cells (Figure 2A and Figure
S5). These data also show that some increased miR-21 expression
in some patients originate from stroma cells. To perform a more
comprehensive analysis, we combined Taqman qPCR arrays with
LCM to examine an enriched cancer cell population. These data
reveal that some of the miRNAs identified in the bulk screen (miR-
370, miR-124, miR-508, miR-509) are likely not expressed in
cancer cells as they were not readily detected in the LCM enriched
population. On the other hand, 11/17 of the miRNAs, including
miR-146a and miR-150, identified in bulk tumor are expressed
Figure 5. Metastatic miRNAs increase surviving cells. A. Treatment of cells with pre-miR-150 mimic modestly increases the cisplatin IC50 in
SKOV-3 and IGROV-1, but not OVCAR-8 cells. Wst-1 assays were performed 48 hours after cisplatin treatment. Graph shows average of 3 biological
replicates. Error bars represent s.e.m. B. Schematic of cisplatin survival assay. Cells are treated twice with high concentrations of cisplatin leading to
survival by approximately 1% of the cells. C. miR-150 and miR-146a are up-regulated in surviving cells after 6 days of 50 mM cisplatin in SKOV-3 and 7
days of 30 mM cisplatin in OVCAR-8 cells compared to untreated, proliferating cells. Data are in duplicate and error bars are s.e.m. The fold change for
miR-150 is very large because miR-150 was not detectable in proliferating cells. Ct was set to maximum cycle tested, 40, to estimate the fold change.
D. Inhibition of miR-146a with 10 nM LNA inhibitor significantly reduces the number of residual cells in SKOV-3 and modestly reduces the surviving
cells in OVCAR-8 after 6 days of 50 mM cisplatin in SKOV-3 and 7 days of 30 mM cisplatin in OVCAR-8 cells. The surviving viable cells were determined
by trypan blue exclusion assay. Biological triplicate experiments are shown. Error bars are s.e.m. E. Transfection of 50 nM pre-miR-146a and pre-miR-
150 increase long term survival after 6 days of 50 mM cisplatin in SKOV-3 and 7 days of 30 mM cisplatin in OVCAR-8 cells.
doi:10.1371/journal.pone.0058226.g005
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and maintain similar expression differences in the LCM enriched
cancer cells.
Expression profiling from both bulk tumor and LCM enriched
cancer cell populations as well as ISH data suggest significant up-
regulation of miR-21 in metastases compared to primary tumors.
miR-21 is well-known to be an anti-apoptotic, pro-survival
miRNA in many cancers, including ovarian [30], and our
preliminary observations also support miR-219s role in promoting
spheroid formation (data not shown). These observations support
the concept that omental metastases may be selected to be more
resistant to chemotherapy having survived escape from the
primary tumor.
miRNAs often down-regulate expression by binding the 39UTR
of mRNAs. The effect on mRNA stability and total RNA levels is
often modest [31,32], assessment of mRNA expression changes
can be difficult to observe. To gain insight into how up-regulated
metastatic miRNAs are mediating proliferation and cisplatin
response, we evaluated their predicted targets. We find that miR-
21, miR-146a and miR-150 mRNA targets are significantly down-
regulated compared to randomly selected equivalently sized gene
sets (Figure S4), consistent with these miRNAs actively repressing
mRNAs in metastatic tumors.
miR-150 is most well-known for its role in regulating B-cell
differentiation and the timing of expression is critical for its proper
role in promoting B cell development [33,34]. Recent reports
suggest that miR-150 can either promote or inhibit tumors
[35,36,37,38], highlighting the common theme of context
dependent functions of miRNAs [39,40]. We do not observe
inverse correlation with the expression of previously identified
miR-150 targets P2RX7 [41] or EGR2 [35] in our primary/
metastatic tumor data.
miR-146a has been identified as a tumor suppressor through
down-regulation of the NFkB activators IRAK1 and TRAF6
[42,43]. However, we find that IRAK1 and TRAF6 are not
expressed in SKOV-3 or OVCAR-8 by qPCR (data not shown).
In some contexts, miR-146a is oncogenic, by suppressing BRCA1
[44] or FAS [45]. We did not observe significant reduction of
BRCA1, BRCA2, or FAS expression upon miR-146a ectopic
expression (data not shown). Suppression of BRCA1 would not
make sense with increased survival, as decreased BRCA1/BRCA2
mediated DNA repair functions are associated with higher
cisplatin sensitivity [46]. Thus, miR-146a appears to work through
a novel mechanism in ovarian cancer cells to increase survival.
We hypothesized that changes in miRNA expression in
metastases compared to primary tumors may indicate functions
in the metastatic environment that differ from the primary tumor
environment. To begin to model how these miRNAs may support
sustained growth and survival of metastatic tumors, we embarked
on a series of functional experiments using established ovarian
cancer cell lines. We used gain and loss of function studies in
cisplatin cell viability assays to find no significant effects of miR-
146a and miR-150 on drug sensitivity or growth in ovarian cancer
cells. Preliminary studies testing migration did not reveal
significant miRNA dependent effects (data not shown). However,
we find that miR-146a and miR-150 mediate the formation and
size of spheroids. As cancer cells escape the primary tumor and
enter the peritoneal cavity, they often form aggregates from 50–
750 mm in size. Spheroids resemble these aggregates isolated from
patients [47] and resemble xenograft tumors better than mono-
layer culture [48]. Some of the changes such as increased
expression of integrins seen in established metastases are also
observed in these spheroids (data not shown) and may reflect the
community effect more reminiscent of human disease [19,47,49].
Our observations that miR-146a is up-regulated in human
omental metastases, with a concomitant decrease in predicted
mRNA targets, and spheroids in conjunction with gain and loss of
function assays all suggest an important role for miR-146a in
formation and maintenance of metastases. These data also support
a role for miR-150, though without loss of function data, the
conclusions based on the functional experiments are not as strong.
Together with the cisplatin tolerance assay, these data support the
possibility that miR-146a and miR-150 are need to support
survival under stressed conditions such as spheroid growth, high
concentrations of cisplatin treatment, and adaptation to new
environment conditions during dissemination in patients.
A caveat of this study is that these cell lines may not recapitulate
key features of cancer cells in tumors, including expression of miR-
150 seen in ovarian tumors. Our inability to properly model
ovarian cancer in vitro or in vivo may be obscuring additional
functions of these miRNAs up-regulated in omental metastases.
Short term cultures of newly derived cell lines or examination of
miRNA function in animal models may be necessary to identify
additional functions of these miRNAs in metastasis. These data
highlight how some miRNAs may be important for survival in
specific conditions and are thus selected for increased expression in
metastases. Future studies examining miR-146a and miR-150
using in vivo models and co-culture systems may help provide
insight into the functions of these miRNAs.
One of the major challenges in treating advanced metastatic
disease is the relatively rapid appearance of recurrent, chemore-
sistant tumors. Our data support the hypothesis that cancer cells in
omental lesions develop into a state distinct from the primary
tumor as defined by differential expression of specific miRNAs.
This hypothesis suggests that deeper examination of metastases is
necessary to improve treatment of ovarian cancer, as distinct
pathways may be activated or repressed, leading to different effects
on growth and survival that impact chemotherapy response. The
importance of many of these factors may not be readily detectable
in primary tumors. Our examination of miR-146a and miR-150
function supports this hypothesis by suggesting that these miRNAs
have significantly increased expression in metastases, in 3D
spheroids, and in surviving cancer cells. These observations
support future examination of larger patient cohorts to test if
specific changes in omental metastases indicate patient survival
better than expression changes in primary tumors. Pharmacolog-
ical inhibition reducing miR-146a and miR-150 levels may be a
novel approach to reduce the likelihood of the emergence of
recurrent drug resistant tumors.
Materials and Methods
Patient material
Serous epithelial ovarian tumors were collected from de-
identified cases using protocol #08-0095 approved by the
Institutional Review Board of the Women’s and Infants Hospital
of Rhode Island. All patients were over age 55 at the time of
diagnosis, stage III or later, with evidence of metastatic disease
from imaging, and all tumors were chemo-naı¨ve. A pathologist
specializing in gynecological cancers examined all specimens (MS).
Samples were snap frozen in liquid nitrogen with no fixation.
Immunohistochemistry
Immunhistochemistry was performed on 4 mm slices of formalin
fixed paraffin embedded (FFPE) tissue with the following
antibodies: CA-125 (Dako) and monoclonal Cytokeratin (Dako).
IHC was performed using a Dako EnVisionTM FLEX detection
system according to manufacturer’s instructions.
Ovarian Cancer Metastatic miRNAs
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RNA Isolation and MicroRNA expression analysis by
Taqman low-density array
Tumor tissue with .70% cancer cells was homogenized with a
Tekmar Tissumizer (Cincinnati, OH). RNA was purified using
miRNeasy kit (Qiagen, Valencia, CA) following the manufactur-
er’s instructions. 500 ng of RNA was reverse-transcribed using the
Taqman MicroRNA Reverse Transcription Kit and the Megaplex
RT primer Human Pool A (Applied Biosystems). The cDNA was
diluted and loaded on to a Taqman Human miRNA Array card A
v. 1.0 (Life Technologies), which contains probes for 377 distinct
miRNAs. The Array cards were run on an ABI HT7900 qPCR
instrument. Ct values were obtained for all miRNAs represented
on the cards and fold changes in expression were calculated using
the DCt method relative to U6 snRNA. For assays targeting
individual miRNAs, 250 ng of total RNA from the bulk tumor or
cell lines was reverse transcribed with only the primers for the
miRNA or U6 snRNA. Equal amounts of cDNA were used for
Taqman assays and analyzed using the DCt method relative to U6
snRNA.
Hierarchical clustering was performed using GENE-E [50] with
distances determined by Pearson Correlation and average linkage.
Laser Capture Microdissection and miRNA measurement
Frozen tumor samples were placed into tissue cryomolds
(25 mm620 mm65 mm, Sakura Finetek USA, INC., Torrance,
CA, USA) and submerged in optimal cutting temperature (OCT)
compound (Sakura). The samples were allowed to solidify on dry
ice and then placed inside a 50 mL conical (Corning Inc.,
Corning, NY, USA) and stored in a 280uC freezer. Microdissec-
tion was performed using the Arcturus PixCell IIe LCM system
(Applied Biosystems, Bedford, MA, USA) as detailed by the
manufacturers protocol and 2000–3000 cancer cells were
collected. Total RNA was extracted using RNeasy minElute
(Qiagen) as per manufacturer’s protocol with modifications to
capture miRNAs during RNA extraction. Five nanograms of total
RNA were reverse-transcribed. The resultant cDNA was amplified
with 15 cycles using the Taqman PreAmp Master Mix and the
Megaplex PreAmp primers, Human Pool A (Life Technologies).
miRNAs were measured using the Taqman qPCR Card A v1.0
(Life Technologies).
For mRNA expression, Affymetrix Gene St arrays measured
mRNA expression from the same RNA as used for the miRNA
measurements. Expression scores were determined by RMA after
quantile normalization. These data will be fully described in a
separate publication. To determine mRNA targets, Targetscan
Release 5.2 [51]and PITA [52] predicted targets were download-
ed. Pearson correlations between the RMA scores from Affymetrix
Gene St arrays compared to the Taqman qPCR miRNA
expression was calculated. Pearson correlations for 1,000 random
permutations of equivalently sized gene sets of all non-targeted
genes were calculated to determine significance of the predicted
mRNA targets. P-values were determined by determining how
often the mean of the distribution of the correlation coefficients for
each random set was lower or higher than the predicted targets.
miRNA ISH
miRNAs in situ hybridization was performed similar to
published protocols [53]. Locked nucleic acids (LNA)-modified
probes were 59 labeled with digoxigenin (Exiqon). After 15 mg/ml
proteinase K disgestion, 30 nM of the probe was hybridized to the
tissue for 15 hours at 62uC. The probe target was visualized by
alkaline phosphatase activity on the nitroblue tetrazolium and
bromochloroindoyl phosphate substrate followed by Nuclear Red
counterstain. ISH was performed by Exiqon.
Cell culture and transfections
SKOV-3 was purchased from the American Type Culture
Collection. IGROV-1 and OVCAR-8 cell lines were purchased
through the National Cancer Institute DTP tumor repository
program. Cells were grown in DMEM (Cellgro) with 10% FBS,
1% Penicillin, and 1% streptomycin (Thermo-Fisher) added. Each
line was authenticated for genotype and phenotype by the source
company. Cells were used at low passage, always less than four
months of passaging post-procurement. Cisplatin was purchased
from Sigma-Aldrich. Pre-mirs (Life Technologies) and Linked
Nucleic Acids (LNAs) (Exiqon) were transfected with Fugene HD
(Promega) with indicated concentrations. Negative Control pre-
mir mimic 2.0 (Cat #4464058, Life Technologies) and miR-
CURY LNA(tm) microRNA inhibitor Negative Control A (Cat #
199004, Exiqon).
Cell Viability, Survival and Spheroid Assays
Cells were plated in 96 well plates and treated with the indicated
concentrations of drug 24 hours later. 96 hours after treatment,
viability was measured using WST-1 (Roche) according to
manufacturer’s protocol. Spheroids were grown in micromolds
(Microtissues, Providence, RI). The area of the 15 spheroids in the
center of each mold was determined in ImageJ. Cells were plated
into the molds 24 hours after transfection. Transfected cells were
transferred to a 3 cm dish for 24 hours. We then treated them with
30–50 mM Cisplatin, as indicated, for 3 days, with a retreatment 3
days later. After 6–7 days as indicated, viable cells were determined
by trypan blue exclusion assay in technical triplicate.
Affymetrix microarrays
Nugen WT-Ovation Pico kit with the WT-Ovation Exon
Module was used to prepare the RNA for Affymetrix Human
Gene St v1.0 microarrays following manufacturer instructions in
the Brown University Center for Genomics and Proteomics core
facility. Data was quantile normalized and signals were estimated
using Robust Multi-array Average (RMA). Genes with consistent
signal below the lowest quartile were removed. Data are deposited
to the Gene Expression Omnibus in series GSE30587.
Supporting Information
Figure S1 Tumors are of ovarian origin and are serous
epithelial as indicated from examination of H&E and
cytokeratin staining. Representative H&E staining of two
representative cases. CA125 and cytokeratin staining of one case is
consistent with ovarian tumor origins.
(TIF)
Figure S2 Bar graph summary of miRNA Taqman
expression data shown in Figure 1A highlighting the
miRNA expression changes in each tumor.
(TIF)
Figure S3 Taqman assays targeting individual miRNAs
and U6 snRNA are consistent with megaplex pooled
Taqman assays from bulk tumor purified RNA. Indiv
indicates assay perform with primers only for the designated
miRNA. Megaplex is the bulk tumor fold change from the pooled
377 miRNA assay used for the screen shown in Figure 1. All fold
changes are calculated using the DCt method relative to U6
snRNA. Data for case 1 and 3 are shown.
(TIF)
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Figure S4 miR-146a and miR-150 predicted mRNA
targets are significantly down-regulated in omental
lesions compared to primary tumors. A. Global distribution
of the Pearson correlation coefficients between mRNAs and
miRNAs in the primary and metastatic tumors. Red line indicates
mRNA targets from the union of TargetScan and PITA
predictions. Grey lines are randomly selected sets of transcripts
of the same size permuted 1,000 times. P-values are calculated by
counting the number of distributions with means lower than the
target distribution to define the background. B. Genes with
Pearson correlation coefficients,20.3 in the tumors are signifi-
cantly enriched for specific pathways and functions as determined
by Ingenuity Pathway Analysis (IPA). P-values are multiple
hypothesis corrected using Benjamini-Hochberg (3). Selected
genes for each pathway are listed.
(TIF)
Figure S5 In situ hybridization of miR-21 in matched
primary tumors and omental metastases. Cancer cells are
stained red by Nuclear Red.
(TIF)
Figure S6 Pictures of the H&E stained cancer cells
before and after laser capture microdissection (LCM).
Pockets of cancer cells were selected for removal and analysis.
(TIF)
Figure S7 The 8 miRNAs expressed in both cell lines
and LCM enriched cancer cells in tumors have increased
expression in spheroids compared to monolayer cell
culture. Taqman qPCR array card data of miRNA expression in
monolayer and spheroids. Fold changes calculated by DCt method
normalized to U6 snRNA.
(TIF)
Figure S8 miR-146a expression after 24 hours after
transfection with 50 nM pre-miR in SKOV-3 and OV-
CAR-8 cells using Taqman assays targeting only miR-
146a. Fold changes calculated by DCt method normalized to U6
snRNA. Control are cells transfected with negative control pre-
miR. Error bars are standard deviation from three independent
experiments transfected in parallel with the functional assays.
(TIF)
Table S1 Summary of Patient Characteristics.
(XLSX)
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